Aeterna Zentaris - Klaus Paulini, President and CEO
Klaus Paulini, President and CEO
Source: Aeterna Zentaris
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Aeterna Zentaris (AEZS) has announced that Novo Nordisk Healthcare AG has exercised its right to terminate the amended development and commercialization licence agreement
  • The agreement was previously entered into between Aeterna’s wholly-owned subsidiary and Novo for Macrilen (macimorelin)
  • Following Novo’s 270-day notice period, Aeterna will regain full U.S. and Canadian rights to the product
  • Aeterna Zentaris Inc. is a specialty biopharmaceutical company
  • Aeterna Zentaris Inc. was down 3.469 per cent, trading at $6.40 as at 11:25 AM ET

Aeterna Zentaris (AEZS) announced that Novo Nordisk Healthcare AG has exercised its right to terminate the amended development and commercialization licence agreement.

The agreement was previously entered into between Aeterna’s wholly-owned subsidiary and Novo for Macrilen (macimorelin).

Macrilen (macimorelin) is the first and only U.S. FDA and European Commission-approved oral test for adult growth hormone deficiency (AGHD) diagnosis.

Following Novo’s 270-day notice period, Aeterna will regain full U.S. and Canadian rights to the product.

The terms of the commercial licence empower Novo Nordisk to return the regulatory approvals and intellectual property and provide certain other assistance to aid in an orderly transition of Macrilen’s (macimorelin) rights to Aeterna.

Until the end of those 270 days, commercial licence requires Novo Nordisk to continue selling and promoting Macrilen (macimorelin) in the U.S., and Novo Nordisk’s financial support of the pivotal safety and efficacy DETECT trial remains unchanged until the end of that notice period.

“We have always strongly believed in the value of macimorelin and remain fully committed to our plans to continue commercialization in the U.S. and Canada as well as continuing the pediatric development in our ongoing DETECT-trial,” stated Dr. Klaus Paulini, Chief Executive Officer of Aeterna.

“Additionally, we believe that macimorelin’s value has the potential to substantially increase as we plan for success with its potential expanded use in CGHD,” he added.

Macimorelin has been marketed in the U.S. by Novo Nordisk under the trade name Macrilen.

Under the commercial licence, Novo Nordisk was granted an exclusive licence for the development, manufacturing, registration and commercialization of Macrilen (macimorelin) in the U.S. and Canada.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need.

Aeterna Zentaris Inc. was down 3.469 per cent, trading at $6.40 as at 11:25 AM ET.


More From The Market Herald
Featured Video Play Icon

" OpSens (TSX:OPS) announces first SavvyWire procedure in the U.S.

OpSens (OPS) is announcing the first SavvyWire procedure in the U.S.

" Lobe Sciences (CSE:LOBE) incorporates Australian subsidiary for psilocin trials

Lobe Sciences (LOBE) has incorporated its wholly-owned Australian subsidiary to facilitate three or more clinical trials.
Featured Video Play Icon

" Rapid Dose Therapeutics (CSE:DOSE) to supply leading gas and convenience store retailer

Rapid Dose (DOSE) has signed a supplier agreement with a leading gas and convenience store retailer.

" NervGen Pharma (TSXV:NGEN) announces leadership changes

NervGen Pharma Corp. (NGEN) has announced several leadership changes.